Among patients who received four-drug consolidation therapy, 84% had measurable residual disease (MRD)-negative status before ...

CHICAGO -- A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; ...

These mutated diseases defy the power of antibiotics. Are illnesses really mutating so fast that we can’t stay ahead of them?

The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a treatment for multiple myeloma.